What NAD infusion studies actually measure

The answer in context

Human infusion research can describe what happens to NAD and related molecules in blood and urine. Those measurements do not, on their own, establish improved energy, cognition or healthy lifespan. The most useful reading starts with the study question before looking at the size of a laboratory change. A striking percentage can answer a narrow pharmacology question while leaving the consumer question almost entirely open.

Inside the six-hour pilot

Grant and colleagues studied 11 healthy men aged 30–55: eight received NAD and three saline. The active infusion delivered 750 mg over six hours, with sampling through hour eight. Plasma NAD rose later in the session; urinary measurements also changed. This was a small metabolic study, not a trial built around fatigue relief or everyday function. These details come from the published methods and results, rather than a clinic description of the paper.

Why plasma is only one compartment

A plasma measurement describes the sampled fluid. It does not show how much intact NAD reached the brain, which cells used it, or whether a person became more capable. Even if an intervention clearly changes a blood marker, the chain from exposure to tissue action to worthwhile benefit still needs testing. Comparing a plasma result after an infusion with whole-blood results after weeks of supplements creates an especially weak product ranking.

What the design leaves unresolved

The study does not provide a reliable estimate of rare adverse effects or the results of repeated commercial courses. Eleven participants cannot represent the many ages, illnesses and concurrent medications encountered in practice. A saline comparison helps interpret the measurements, but does not turn an exploratory experiment into proof of broad effectiveness. Larger randomized studies would need prespecified clinical outcomes, adequate follow-up and reporting of withdrawals as well as average results.

What to ask a clinic

Ask which published trial supports the particular outcome being offered, and whether it tested the same molecule, route and population. Request a complete quote including visits, supplies and any required course. Product quality deserves a separate discussion: FDA has reported chills, shaking, vomiting and fatigue after NAD injectables, sometimes requiring medical treatment. That alert concerns ingredient suitability and possible contamination; it does not supply a frequency estimate for every clinic or formulation.

A better way to read a percentage

Imagine two services both cite a large rise in NAD, but one measures plasma immediately after a session and the other measures whole blood after repeated oral use. There is no common clinical yardstick in those numbers. Before interpreting the difference, write down the specimen, collection time, reference value and outcome in ordinary language. If those entries differ, the percentages are answering different questions.

A useful publication should also make the absolute scale understandable where it is reported. Relative changes can look dramatic when the starting value is small. That is a reason to inspect the original measurements, not a reason to dismiss the research. It keeps an exploratory result from carrying a promise it was never designed to support.

A proportionate purchasing decision

Paying for a longer appointment or a more direct route buys a service with different logistics. It does not buy stronger evidence automatically. A useful decision statement names the hoped-for outcome, the uncertainty accepted and the total financial commitment. Our delivery-format comparison can organize those practical differences, while the references below show why a blood response should not be presented as a demonstrated rejuvenation result.